 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Otsuka Pharmaceutical |
| Street 1: | 2-9, Kanda Tsukasa-machi, Chiyoda-ku |
| Street 2: | |
| City: | Tokyo |
| Province: | |
| Post Code: | 101-8535 |
| Country: | Japan |
| Phone: | +49 89 2060205-00 |
| Organization Email: | reception@otsuka-onpg.com |
| Web Site: | http://otsuka-onpg.com/ |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| In line with its corporate philosophy, Otsuka’s drug research and development efforts are focused on providing innovative products that improve health worldwide. There are many kinds of health issues facing us today, but TB remains an insurmountable disease that affects millions of people around the world. The company’s philosophy is to address true unmet medical needs and Otsuka saw TB as a unique area of contribution, as no other companies were attempting to tackle this major issue. Otsuka has had a TB drug discovery program for over 30 years and has been a recognized leader in TB research through its commitment to the discovery and development of new compounds as well as the building of a clinical infrastructure within developing countries affected by the disease. As such, Otsuka is recognized as the largest funder of TB drug development worldwide. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Advocacy Provision of drugs, diagnostics and commodities Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 51 - 99 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Stop TB communications |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Information on developments within the TB world |
| Are you a member of a Stop TB national partnership: | Japan |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Otsuka conducts clinical trials in Japan, among other countries, for the development of novel compounds for the treatment of multidrug-resistant tuberculosis (MDR-TB). | |
Geographical Reach | |
| Which country is your headquarters located in: | Japan |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
China Czech Republic Egypt Estonia France Germany Indonesia Italy Japan Latvia Lithuania Pakistan Peru Philippines Republic of Korea Republic of Moldova South Africa Spain Sweden Switzerland United Kingdom of Great Britain and Northern Ireland United States of America Viet Nam |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: As a recognized leader in TB R&D, Otsuka is committed to helping eliminate this devastating disease. For more than 30 years Otsuka has made TB research a priority, and is currently working on the development of a novel compound for multidrug-resistant TB (MDR-TB). More information may be found at: http://clinicaltrials.gov/ct2/show/NCT01424670 TB-HIV: As part of our Phase III clinical trial, MDR-TB study subjects with co-existing HIV infection who are currently taking antiretrovirals (ARVs) will be randomized to receive six months of delamanid plus an optimized background regimen (OBR) according to WHO treatment guidelines or placebo plus OBR. Laboratory Strengthening: Otsuka engaged in capacity building and infrastructure development in many clinical sites in the nine countries where the Phase II trial of delamanid took place. This unique investment included infrared lighting, larger hospital rooms with better ventilation, laboratory equipment and extensive training in some locations. All sites in which we operate followed the most stringent Good Clinical Practice (GCP) standards. Our work in this area underscores the company’s strong commitment to MDR-TB treatment beyond the testing of our new compound. New TB Drugs: Continuing its commitment to TB R&D, a Phase 3 trial is underway which includes six months of treatment with delamanid plus OBR in patients with MDR-TB, including those with co-existing HIV infection. The trial is currently ongoing in Latvia, Lithuania, Estonia, Moldova, Philippines, Peru, and South Africa. Additionally, a clinical program exploring the use of delamanid in pediatric MDR-TB using a dispersible formulation for use with younger children and infants is currently underway. http://clinicaltrials.gov/ct2/show/NCT01424670 |
|
Declaration | |
| Declaration of interests: I am a full-time employee of Otsuka Pharmaceutical Co., Ltd. | |
| Application date: | February 4, 2010 |
| Last updated: | April 23, 2024 |